| ¿µ¹® | host | ÇÑ±Û | ¼÷ÁÖ |
|---|---|---|---|
| ¼³¸í | ´Ù¸¥ »ý¹°(±â»ýü)À» ±â»ý½ÃÄÑ, ¿µ¾çÀ» °ø±ÞÇÏ´Â µ¿¹° ¶Ç´Â ½Ä¹°. ¸¶Áö¸·ÀÇ ¼öÁÖ¸¦ Á¾¼÷ÁÖ, ¹ßÀ°ÀÇ µµÁß¿¡ ±â»ýÇÏ´Â ¼÷ÁÖ¸¦ Áß°£ ¼÷ÁÖ¶ó°í ÇÑ´Ù. ±â»ýµ¿¹° Áß¿¡´Â ¼÷ÁÖ°¡ ƯÁ¤ÇÑ Á¾ÀÏ ¶§µµ ÀÖ°í ¶Ç ¸¹Àº ±â»ýÃæ°ú °°ÀÌ±× ¹ß»ý´Ü°è¿¡ µû¶ó ¸¹Àº Á¾·ùÀÇ ¼÷ÁÖ¸¦ ÇÊ¿ä·Î ÇÏ´Â °Íµµ ÀÖ´Ù. ÀÌ °æ¿ì ¾Ö¹ú·¹°¡ ±â»ýÇÏ´Â ¼÷ÁÖ¸¦ Áß°£¼÷ÁÖ, ¼ºÃ¼°¡ ±â»ýÇÏ´Â ¼÷ÁÖ¸¦ ÃÖÁ¾¼÷ÁÖ¶ó°í ÇÑ´Ù. °£ÁúÀÎ °æ¿ì¿¡´Â ¹°°íµ¿ÀÌ Áß°£¼÷ÁÖÀ̰í, ¼Ò-¾ç µîÀº ÃÖÁ¾¼÷ÁÖ°¡ µÈ´Ù. ±â»ý½Ä¹°¿¡´Â °Ü¿ì»ìÀÌ¿Í °°ÀÌ Á¹Âü³ª¹« µîÀ» ¼÷ÁÖ·Î ÇÏ¿© ½º½º·Î ±¤ÇÕ¼ºÀ» Çϸ鼵µ ¼÷ÁÖ¿¡°Ô¼ ¿µ¾çÀ» ¾ò´Â °Í°ú, ¾ß°í¿Í °°ÀÌ »ý° µîÀÇ »Ñ¸®¸¦ ¼÷ÁÖ·Î ÇÏ¿© ¼÷ÁÖ¿¡°Ô¼¸¸ ¿µ¾çÀ» ÀÇÁ¸ÇÏ´Â °ÍÀÌ ÀÖ´Ù. ±â»ý»ý¹°¿¡´Â ÀÌ ¹Û¿¡µµ »ý¹°ÀÇ »çü³ª ±× ºÐÇØÁß¿¡ ÀÖ´Â °Í, ¹èÃâ¹° µîÀ» ¼÷ÁÖ·Î ÇÏ´Â °Íµµ ÀÖ´Ù. |
||
| ¿µ¹® | graft versus host reaction | ÇÑ±Û | ÀÌ½ÄÆí´ë ¼÷ÁÖ¹ÝÀÀ |
|---|---|---|---|
| ¼³¸í | ¸é¿ªÀ̶õ ÀÚ½ÅÀÇ °Í°ú ÀÚ½ÅÀÇ °ÍÀÌ ¾Æ´Ñ °ÍÀ» ±¸ºÐÇØ¼ ÀÚ½ÅÀÇ °ÍÀÌ ¾Æ´Ñ °ÍÀ» °ø°ÝÇÏ¿© »ý¹°ÇÐÀû Ȱ¼ºÀ» ¾ø¾Ö°Å³ª Á¦°ÅÇÏ´Â °ÍÀÌ´Ù. ÀÌ ¸é¿ªÀº ÁÖ·Î Ç÷¾×¿¡ ÀÖ´Â ¼¼Æ÷¿¡ ÀÇÇØ¼ ÀÌ·ç¾îÁø´Ù. ƯÈ÷ ¸²ÇÁ±¸´Â ÀÌ ¸é¿ª¿¡ ÁßÃßÀûÀÎ ¿ªÇÒÀ» ÇÏ´Â ¼¼Æ÷ÀÌ´Ù. ÀÌ½ÄÆí´ë¼÷ÁÖ¹ÝÀÀÀ̶ó´Â °ÍÀº À̽ĵǾî¿Â Á¶Á÷¿¡ Á¸ÀçÇϴ ŸÀÎÀÇ Ç÷±¸µéÀÌ ¼÷ÁÖÀÇ ¼¼Æ÷¸¦ °ø°ÝÇÏ´Â °ÍÀ» ¸»ÇÑ´Ù. Áï À̽ĵǾî¿Â Á¶Á÷°ú ÇÔ²² µé¾î¿Â Ç÷±¸µéÀÌ À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ ¼¼Æ÷¸¦ ŸÀÎÀÇ °ÍÀ¸·Î ÀÎÁöÇØ¼ °ø°ÝÇÏ´Â Çö»óÀÌ´Ù. À̰ÍÀº À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ ¸é¿ª»óŰ¡ Á¤»óÀûÀÏ °æ¿ì¿¡´Â ÀϾÁö ¾Ê´Âµ¥ ¿Ö³ÄÇÏ¸é ¸é¿ª»óŰ¡ Á¤»óÀÏ °æ¿ì¿¡´Â À̽ĵǾî¿Â Àå±â¿Í ´õºÒ¾î µé¾î¿Â ŸÀÎÀÇ Ç÷±¸µéÀ» À̽ÄÀ» ¹ÞÀº »ç¶÷ÀÇ Ç÷±¸°¡ ŸÀÎÀÇ °ÍÀ¸·Î ÀÎÁöÇØ¼ °ø°ÝÀ» ÇÏ°í ¼ýÀûÀ¸·Î À¯¸®ÇÏ¿© ¸ðµÎ Á×ÀÏ ¼ö°¡ Àֱ⠶§¹®ÀÌ´Ù. |
||
| IHF | Industrial Health Foundation; integration host factor; International Hospital Foundation |
|---|---|
| ANF | Atrial Natriuretic Factors |
| ECF | 1) Eosinophilic Chemotatic Factors 2) Extra-Cellular Fluid; ¼¼Æ÷ ¿Ü¾× |
| NCF | Neutrophilic Chemotatic Factors |
| CDSRF | chronic disease and sociodemographic risk factors |
| IHF | Integration Host Factor |
|---|---|
| CIQ | Community Integration Questionnaire |
| PIC | pre-integration complex |
| REMI | Restriction Enzyme Mediated Integration |
| VMI | Visual Motor Integration |
| virus integration | Insertion of viral DNA into host-cell DNA. This includes integration of phage DNA into bacterial DNA (lysogeny) to form a prophage or integration of retroviral DNA into cellular DNA to form a provirus. (12 Dec 1998) |
|---|---|
| personality integration | The effective organization of old and new experience, data, and emotional capacities into the personality; the harmonious organization of the personality. (05 Mar 2000) |
| systems integration | The procedures involved in combining separately developed modules, components, or subsystems so that they work together as a complete system. (12 Dec 1998) |
| integration | <molecular biology, virology> Incorporation of the genetic material of a virus in to the host genome. (18 Nov 1997) |
| accidental host | One that harbors an organism which usually does not infect it. (05 Mar 2000) |
| amplifier host | A host in which infectious agents multiply rapidly to high levels, providing an important source of infection for vectors in vector-borne diseases. (05 Mar 2000) |
| parasite-host ecosystem | Complex of all parasite species and individuals associated with a specific host. Synonym: parasite-host ecosystem. Origin: parasite + G. Koinos, common, together (05 Mar 2000) |
| paratenic host | An intermediate host in which no development of the parasite occurs, although its presence may be required as an essential link in the completion of the parasite's life cycle; e.g., the successive fish host's that carry the plerocercoid of Diphyllobothrium latum, the broad fish tapeworm, to larger food fish eventually eaten by man or other final host's. Synonym: transport host. (05 Mar 2000) |
| reservoir host | The host of an infection in which the infectious agent multiplies and/or develops, and upon which the agent is dependent for survival in nature; the host essential for the maintenance of the infection during times when active transmission is not occurring. (05 Mar 2000) |
| graft-versus-host disease | <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue. When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage. The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign. The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin. Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel. Synonym: GVH disease. Acronym: GVHD (20 Sep 2002) |
| graft-versus-host reaction | <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue. When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage. The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign. The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin. Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel. Synonym: GVH disease. Acronym: GVHD (20 Sep 2002) |
| graft-versus-host response | <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue. When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage. The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign. The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs. Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin. Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel. Synonym: GVH disease. Acronym: GVHD (20 Sep 2002) |
| cutaneous graft versus host reaction | An acute erythematous maculopapular reaction with bulla formation in the most severe cases; chronic changes may resemble lichen planus or scleroderma. (05 Mar 2000) |
| secondary host | <epidemiology> See vector. (05 Dec 1998) |
| host | An organism that is infected with or is fed upon by a parasitic or pathogenic organism (for example, a virus, nematode, fungus). The term can also be applied, loosely, to a plant supporting an epiphyte. (09 Oct 1997) |
Synonyms : Host Factor, Host Factor Protein, Host Factors, Integration Host Factor alpha Subunit, Integration Host Factor beta Subunit, Factors, Integration Host, Host Factors, Integration
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|